CONCLUSION
Wheezing occurs under the age of 5 for a variety of reasons. If the patient with recurrent wheezing is evaluated well from the first admission and treated according to wheezing after underlying diseases such as gastroesophageal reflux, cystic fibrosis, ciliary dyskinesia, cardiac and pulmonary anomalies are ruled out, both hospital admissions and attacks will be prevented due to unnecessary treatments and exacerbations of wheezing. In this study, it was observed that the frequency of exacerbation was reduced by 90.9% in the first control with the use of montelukast in the group with mAPI negative EVW. It was seen that this effect continued in the 2nd control. With this study, we believe montelukast may be a potential treatment option for EVW in preschool children. This approach is an attractive therapeutic option since it has the potential to reduce systemic steroid exposure and hospitalizations. Studies with a larger patient population are needed to better elucidate the role of montelukast in the management of EVW.